NAMs Empower Translational Research

Title : NAMs Empower Translational Research

Webinar Overview :

In April, the FDA announced that New Approach Methodologies (NAMs) will be encouraged to include in IND applications, while reducing the animal testing requirements. This webinar will provide three key technologies relevant to NAMs. These technologies can be introduced prior to IND or clinical studies.

1. To accelerate drug development, Axcelead collaborates with hospitals to build evaluation systems using fresh human cancer tissues. Alongside human brain organoids and immune-humanized mouse models, these tools improve drug assessment and support advances in neurological diseases, immuno-oncology and personalized medicine.
2. A major challenge in translational research is linking complex molecular data to actionable insights for drug development. The second speaker introduces Axcelead’s multilayer Omics platform—including non-targeted metabolomics, clinical proteomics, and single-cell transcriptomics—to accelerate MoA elucidation and biomarker development.
3. VitroVo founders are leaders in microelectrode array (MEA)-based in vitro compound evaluation, contributing to consortia like HESI. Using iPSC-derived models and advanced analytics with its decades of experience, VitroVo does not only support toxicity risk detection but also disease modeling and phenotypic screening to better predict in vivo outcomes.

Key Takeaways

• Learn how cutting-edge evaluation systems using fresh human cancer tissues, human organoids, and immune-humanized mouse models are accelerating translational research
• Explore how Axcelead’s advanced omics technologies can help you unravel complex biological mechanisms
• Discover how VitroVo’s state-of-the-art MEA-based assays enable early and accurate detection of drug-induced toxicity